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Abstract
Objective To determine the relative costs, effects, and cost effectiveness
of selected interventions to control cataract, trachoma, refractive error,
hearing loss, meningitis and chronic otitis media.
Design Cost effectiveness analysis of or combined strategies for
controlling vision and hearing loss by means of a lifetime population
model.
Setting Two World Health Organization sub-regions of the world where
vision and hearing loss are major burdens: sub-Saharan Africa and
South East Asia.
Data sources Biological and behavioural parameters from clinical and
observational studies and population based surveys. Intervention effects
and resource inputs based on published reports, expert opinion, and the
WHO-CHOICE database.
Main outcome measures Cost per disability adjusted life year (DALY)
averted, expressed in international dollars ($Int) for the year 2005.
Results Treatment of chronic otitis media, extracapsular cataract surgery,
trichiasis surgery, treatment for meningitis, and annual screening of
schoolchildren for refractive error are among the most cost effective
interventions to control hearing and vision impairment, with the cost per
DALY averted <$Int285 in both regions. Screening of both schoolchildren
(annually) and adults (every five years) for hearing loss costs around
$Int1000 per DALY averted. These interventions can be considered
highly cost effective. Mass treatment with azithromycin to control
trachoma can be considered cost effective in the African but not the
South East Asian sub-region.
Conclusions Vision and hearing impairment control interventions are
generally cost effective. To decide whether substantial investments in
these interventions is warranted, this finding should be considered in
relation to the economic attractiveness of other, existing or new,
interventions in health.
Introduction
Throughout the world, loss of vision and hearing are a major
burden. More than 284 million people are visually impaired, of
whom 245 million have low vision and 39 million are blind.
1
Some 278 million people worldwide have moderate or greater
hearing impairment.
2-5 The number of people worldwide with
sensory deficits is rising mainly due to a growing global
population and longer life expectancies. More than 90% of the
world’s visually impaired people and 80% of hearing impaired
people live in low and middle income countries.
1 6
Cataract is the leading cause of visual impairment globally,
followed by glaucoma. The most common type of hearing
impairment is sensorineural hearing loss (with common causes
advanced age and noise exposure), followed by conductive
hearing impairment (with leading cause chronic otitis media).
Globally, up to 75% of all vision loss and 50% of hearing loss
is avoidable.
1 6
Forthisreason,globalinitiativeshavesettargetsandindicators
related to the reduction of vision and hearing impairment, with
special reference to low and middle income countries. VISION
2020, the global initiative for the elimination of avoidable
blindness, aims to eliminate avoidable blindness by the year
2020 and prevent the projected doubling of avoidable visual
impairmentbetween1990and2020.
7WWHearing(World-Wide
HearingCareforDevelopingCountries)aimstoeliminatemuch
ofavoidablehearinglossby2020throughanewinitiativecalled
Audio 2020.
8
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Research
RESEARCHFor many countries, it is not evident that these targets will be
achieved at current rates of progress, despite a wide range of
effective interventions to prevent, detect, and manage visual
and hearing impairment. A key question, therefore, is whether
the correct mix of interventions is currently being used, and
what strategies should be scaled up if additional funds would
become available. Cost and cost effectiveness analyses can
provide valuable inputs to these decisions by identifying the
most efficient ways of delivering prevention, diagnosis, and
treatment services at different levels of resource availability.
Several studies have reported on the global and regional cost
effectiveness of interventions targeting cataract,
9 trachoma,
10
refractive error,
11 and different causes of hearing impairment.
12
However, studies have been carried out in isolation, which
prevents the cost effectiveness of the different interventions
being directly compared. In addition, the studies used
demographics and price levels for the year 2000.
Now, a decade past 2000, and in the realm of the global
initiatives, an up to date assessment of the cost effectiveness of
vision and hearing impairment control strategies is needed. In
this paper we address the question of what are the costs and
effects of prevention, early detection, management, and
rehabilitationofvisualandhearingimpairment,bothsinglyand
in combination. Our analysis is based on a consistent
methodologicalapproachandagenericmeasureofeffectiveness
and covers two geographical settings, in Asia and Africa.
Methods
General approach
Cost effectiveness analysis can be undertaken in many ways,
andtherehavebeenseveralattemptstodevelopmethodological
guidelines to make results more comparable. In its
WHO-CHOICE project, the World Health Organization has
developed a standardised set of methods and tools that can be
used to analyse the societal costs and effectiveness of current
and possible new interventions simultaneously.
13 14 The project
is designed to provide regularly updated databases on the costs
andtheeffectsofafullrangeofpromotive,preventive,curative,
and rehabilitative health interventions.
Regions analysed
Mostcountriesdonothavethecapacitytoevaluateallpotential
interventions for improving given health indicators at the
nationalandthesub-nationallevel,andglobalestimatesaretoo
general and of little use to any specific country. However,
countries may benefit from regional evaluations of data, where
data of neighbouring countries with similar settings are pooled.
The present analysis drew on a comprehensive examination of
14 world sub-regions defined by geographical proximity and
epidemiology according to WHO classification. In common
with other papers in this series, we evaluated interventions for
two major global regions using a standardised analytical
approach.Thetworegionsarereferredtoassub-SaharanAfrica,
includingthoseAfricancountrieswithveryhighadultandhigh
child mortality (referred to as AfrE in the WHO classification),
andSouthEastAsia,includingthosecountriesinAsiawithhigh
adult and high child mortality (referred to as SearD).
15 The
prevalence of vision and hearing impairment globally and for
thesetworegionsissummarisedintable1⇓(basedonResnikoff
et al
16 17 and Mathers
18).
Interventions analysed
Table 2⇓ shows the set of 87 analysed interventions (and
combinations of interventions) to control cataract, trachoma,
refractiveerror,hearingloss,meningitis,orchronicotitismedia.
We carefully selected the interventions on their relevance for
disease control but were also limited by the lack of data on
burden of disease or intervention effectiveness. Some
interventionsthathaverelativelyrecentlybeendevelopedwere
not subjected to analyses. The resulting set of interventions is
therefore somewhat arbitrary and not meant to cover all
potentially available interventions to reduce hearing and vision
loss in sub-Saharan Africa and South East Asia. For example,
in trachoma control we evaluated antibiotic treatment and
surgerybutnotpromotionoffacewashing.Likewise,incataract
control, we evaluated extracapsular cataract extraction but not
smallincisioncataractsurgeryorphacoemulsification.Incontrol
of hearing impairment, we did not evaluate education,
rehabilitation,andnoiseconservationprogrammes,norneonatal
screening, surgical interventions, or cochlear implants.
Interventions on glaucoma were also not evaluated. All
interventions are defined in appendix A on bmj.com.
AllinterventionswereanalysedatWHO-CHOICEstandardised
geographic coverage levels of 50%, 80%, and 95%, referring
to the percentage of eligible cases receiving treatment. These
levelsmaynotalwaysbefeasible,butareneverthelessreported
here to show the presence of important (dis)economies of scale
when varying the number of people covered.
Estimating health effects
The starting point of our analysis of health effects was the
identification of best available evidence on the (clinical or
population)effectivenessofinterventions.Ideally,weretrieved
this evidence from Cochrane reviews (such as on the
effectivenessofcataractsurgery),butinotherinstancesweused
evidence from individual studies (such as on the effectiveness
of azithromycin in trachoma control). Where no evidence was
available, we based our estimate of effectiveness on expert
opinion (such as on levels of compliance in wearing hearing
aidsorglasses).Weusedevidenceoninterventioneffectiveness
pertaining to the regions under study or extrapolated this from
Western settings where meaningful (as for antibiotic treatment
formeningitis).Allsourcesofdataofinterventioneffectiveness
for screening interventions for uncorrected refractive error are
listed in table 3⇓, and those for the other disease areas are listed
in the appendices on bmj.com.
All analyses used population model PopMod
19 to translate this
intervention effectiveness into a generic measure of health
effects. More specifically, it combines incidence, prevalence,
and mortality data for the relevant causes of vision and hearing
impairmentwiththestandardhealthstatevaluations
20toestimate
the population impact of the different scenarios in terms of
healthy years lived.
14 Following standardised WHO-CHOICE
cost effectiveness analysis, we evaluated all interventions for a
period of 10 years, and ran model for the length of time
necessary for all people affected by the interventions to have
died (that is, some 100 years in both regions, following the use
ofregionalmortalityrates
18).Thedifferencebetweenthehealthy
yearslivedineachinterventionscenarioandthenointervention
scenario is the health gain of the intervention, or the number of
disability adjusted life years (DALYs) averted. A general
description of the population model is provided in the general
appendixonbmj.com,anddetailsofthedifferentdiseasemodels
are available in appendix A on bmj.com.
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The analysis follows standardised WHO-CHOICE guidelines
on costing analysis, and estimates patient level costs and
programme level costs from the societal perspective. Patient
level costs are all costs incurred at the level of contact between
the provider and the individual patient. The quantities of
resources required in terms of diagnostic tests, drug use, and
health centre visits for supervision and monitoring and
hospitalisationforeachoftheinterventionswerebasedonWHO
treatment protocols and expert opinion of actual practice. Drug
costs were based on international drug prices
21 with a mark up
for international and local transportation costs.
22 23 Unit costs
of health centre visits and hospital inpatient days were based
on econometric analysis by Adam et al,
24 while those for
laboratory tests and x rays were based on the best available
international cost information included in WHO-CHOICE’s
costing database. Unit costs were combined with resource use
patterns to estimate the cost per patient treated. Total patient
costs were then calculated as the cost per patient treated
multiplied by the number of patients treated (calculated as the
annual incidence of disease from the model multiplied by the
relevant coverage level and then by the percentage of cases
diagnosed and treated in covered areas). The costs of screening
interventions to detect hearing and vision impairment not only
include the costs of the screening activities but also costs of
hearing aids and glasses for those who need them.
Programme level costs relate to the resource inputs used in the
production of an intervention at a level above that of the patient
orprovidingfacility,suchascentralplanningandadministration
functions, supervision, and training. Estimated quantities of
resources required for central planning and administration at
national, provincial and district levels were based on a series of
evaluations made by WHO-CHOICE costing experts in the
different sub-regions and validated against the literature
(categories of resource input included personnel, training,
materials and supplies, media, transport, maintenance, utilities
and capital.
22 Details of all cost calculations are found in
appendixAonbmj.comandpreviouslypublishedpapers.
9-12An
example of all variable inputs including its sources is provided
in table 3⇓, for the cost effectiveness analysis of screening
strategiesforuncorrectedrefractiveerroramongschoolchildren
in sub-Saharan Africa.
Following the WHO-CHOICE standardised approach, we
assumed that interventions were performed optimally (that is,
no undertreatment or overtreatment at the highest efficiency
level).
14 All costs were reported in international dollars ($Int)
for the year 2005 to facilitate more meaningful comparisons
across regions ($Int1 buys the same quantity of healthcare
resources in the sub-Saharan African and South East Asian
regions as it does in the United States). For example, cost
estimates in sub-Saharan Africa in $Int should be divided by a
factor2.3toobtainUS$costestimatesforKenya(inSouthEast
Asia cost estimates should be divided by a factor 3.1 to obtain
US$ cost estimates for India).
15 All costs and effects are
discounted at 3%, following standardised WHO-CHOICE
analysis.
14
Estimating cost effectiveness
We rank ordered interventions on the basis of their cost
effectivenessinanumberofstandardisedsteps.
14Firstly,within
each disease area, we calculated the average cost effectiveness
ratios for every intervention by dividing its total number of
DALYs averted by its total costs. Secondly, again within each
disease area, we considered only those interventions that were
bothmoreeffectiveandlesscostlythanotherinterventions.We
thencalculatedtheincrementalcosteffectivenessratioforthose
resulting interventions by dividing the incremental costs by the
incremental health effects. The economic attractiveness of an
intervention within its disease area is reflected by this
incremental cost effectiveness ratio: the lower the incremental
cost per DALY averted, the more economically attractive an
intervention is. Thirdly, we compared resulting interventions
across disease areas on the basis of their incremental cost
effectiveness ratios and ranked them accordingly. The
interventions with the lowest incremental cost effectiveness
ratio are ranked highest and are economically most attractive.
WHO-CHOICE defines interventions that have an incremental
cost effectiveness ratio of less than the gross domestic product
(GDP) per capita as very cost effective, and those with a ratio
less than three times the GDP per capita as cost effective. The
regionsstudiedherehaveaGDPofaround$Int2000percapita,
30
which means that interventions costing <$Int2000 per DALY
averted can be considered very cost effective and those costing
between$Int2000and$Int6000canbeconsideredcosteffective.
Other interventions are considered not cost effective.
Uncertainty analysis
Allinterventionsareimbuedwithacertaindegreeofuncertainty.
To handle this aspect of reporting for such a wide range of
interventions, we classified interventions according to their
degree of cost effectiveness (not cost effective, cost effective,
or very cost effective) in order to ascertain order of magnitude
differences in cost effectiveness. In addition, we undertook a
probabilistic uncertainty analysis using MCLeague software
31
to assess the impact of alternative assumptions on costs and
effects (which were each varied with plus and minus 25% of
their baseline values) on the classification of interventions.
Model adaptations
A few modifications were made to previously published
analyses.
9-12 Firstly, interventions were considered during the
10yearperiod2005to2015ratherthantheperiod2000–10,and
costswerereportedatpricelevelsforyear2005insteadof2000.
Secondly, because of variations in the reporting of coverage
levels in previous studies, interventions were evaluated at
standardisedgeographiccoveragelevelsof50%,80%,and95%.
Thirdly, assumptions on screening, patient, training, and
intervention programme costs were revisited to make results
consistent across the analysis. For example, recent price
reductions of azithromycin after patent expiry were included in
the analysis on trachoma control.
Results
Following the stepwise approach to the rank ordering of
interventions on the basis of their cost effectiveness, we first
report the average cost effectiveness ratios of all interventions
within each disease area (appendix table B1 on bmj.com).
Second, we report the incremental cost effectiveness ratios for
those interventions that both cost less and provide more health
effectsthanotherinterventions,andtheseindicatetheeconomic
attractiveness of interventions within each disease area (same
table).
Intrachomacontrol,trichiasissurgeryisthemostcosteffective
intervention, followed by mass treatment with azithromycin in
both regions. Both mass treatment with tetracycline ointment
andtargetedtreatmentwithazithromycinarenotcosteffective.
In cataract control, extracapsular cataract surgery dominates
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screening of children and adults for hearing disorders (in
combination with provision of hearing aids) is most cost
effective, followed by screening of adults every five years and
annual screening of primary and secondary school children.
Screening of adults every 10 years is not cost effective. For
treatment of chronic otitis media, treatment with topical
antibioticsisthemostcosteffectiveinterventioninbothregions.
For screening for refractive error (including the provision of
spectacles), screening of all primary and secondary school
children is most cost effective in sub-Saharan Africa. In South
East Asia, screening of secondary school children is most cost
effective,followedbyscreeningofbothprimaryandsecondary
school children.
In a third step, we rank interventions according to their
incremental cost effectiveness ratio across all disease areas
(tables 4⇓ and 5⇓ for sub-Saharan Africa and South East Asia).
This is illustrated in the figure⇓ for sub-Saharan Africa.
Implementation of all cost effective interventions would cost
around $Int19 per capita in sub-Saharan Africa.
In both regions treatment of chronic otitis media with topical
antibiotics is the most cost effective intervention, with an
average cost per DALY averted of <$Int63 at all levels. In
sub-Saharan Africa the next most cost effective interventions
are trichiasis surgery, extracapsular cataract surgery, annual
screening of all primary and secondary school children for
refractive error, and treatment for meningitis with ceftriaxione.
In South East Asia the next most cost effective interventions
are treatment of meningitis with ceftriaxione, extracapsular
cataract surgery, screening of all primary and secondary school
children for refractive error, and trichiasis surgery. In both
regionstheseinterventionsallcost<$Int285perDALYaverted
(incremental cost effectiveness ratio, with the exact order of
interventions dependent on coverage level). In both regions
introducing screening for hearing impairment in combination
with the delivery of hearing aids, at 80% coverage level costs
around $Int1000 per DALY averted. According to
WHO-CHOICE benchmark on cost effectiveness, these
interventions can all be considered very cost effective. Mass
treatment with azithromycin is the least cost effective
interventioninbothregionsbutcan,dependingonthecoverage
level, still be considered cost effective in the sub-Saharan
African region. In the absence of any budgetary constraint
implementation of all interventions would lead to a total health
gain of up to 32 million DALYs in sub-Saharan Africa and 84
million DALYs in South East Asia.
The probabilistic uncertainty analysis depicted in appendix C
on bmj.com shows the impact of plausible variations in total
costs and total effects and shows that the average cost
effectiveness ratios of most interventions would retain their
classification of highly cost effective or cost effective after
taking into account such uncertainty. A similar logic would
apply to the incremental cost effectiveness ratio.
Discussion
Principal findings
Treatmentofchronicotitismedia,extracapsularcataractsurgery,
trichiasissurgery,treatmentformeningitis,andannualscreening
of school children for refractive error are among the most cost
effective interventions available to control hearing and vision
impairment, with the cost per DALY averted <$Int285 in both
regions.Screeningofbothschoolchildren(annually)andadults
(every five years) for hearing loss costs around $Int1000 per
DALY averted. These interventions can be considered highly
cost effective. Mass treatment with azithromycin to control
trachoma can be considered cost effective in the sub-Saharan
African but not the South East Asian region.
Strengths and limitations
The analysis has several limitations. Firstly, we performed our
analysis at the regional level, but important differences in costs
or effectiveness of interventions may exist between countries
inthesameregion.Sincedecisionmakingismadeatthecountry
(as opposed to regional) level, more refined estimates of costs,
effects, and cost effectiveness should be made at the country
level, based on country-specific data. A good example is the
contextualisation of WHO-CHOICE regional results to the
country level in Mexico, as reported in this series.
32
Secondly, assumptions on intervention effectiveness are based
on a variety of sources and may reflect contexts other than the
regions analysed—the same level of effectiveness may not
always be realised in reality, and results should be interpreted
withcaution.Yet,ourprobabilisticuncertaintyanalysisindicates
that our study results are robust to alternative assumptions.
These issues are discussed in detail in previously published
papers.
9-12
Thirdly,wedidnotevaluateallpossibleinterventionsthatcould
reduce vision or hearing loss, and our choice of interventions
is somewhat arbitrary. Policymakers should be aware of this,
and should not limit their choice of interventions to those
included in this analysis.
Fourthly, and more specifically, we evaluated screening for
hearing disorders as carried out by trained primary health
workers(incurringhealthcarecosts),andscreeningforrefractive
error as carried out by trained school teachers (who incur no
healthcare costs). However, alternative assumptions have only
limited impact on study results.
Fifthly, in the absence of reliable data, we did not include time
costsofpeopleseekingandundergoingcare,nordidweinclude
changes in productivity losses as a result of the interventions.
The perspective of analysis is therefore not truly societal.
Inclusion of productivity gains after reductions in vision and
hearinglosswouldrendertheinterventionsmorecosteffective.
Sixthly, we assumed that all interventions were implemented
at a relatively high efficiency level—which allows an equal
comparisonbetweenthecosteffectivenessofinterventionsand
avoids the complications from interventions that were not
implemented well would be disadvantaged in comparison with
those that were well implemented.
Lastly, the analysis evaluates interventions at 50%, 80%, and
95% geographic coverage levels, following standardised
WHO-CHOICEmethodology.Thehighercoveragelevelsmay
not always be achievable but are included to indicate the
economies of scale that may take place when more people are
reached with an intervention.
23
The above limitations should be considered in the overall aim
of WHO-CHOICE analysis to provide broad indications on the
cost effectiveness of a range of interventions to inform general
policy discussions, rather than to deliver precise estimates on
a specific intervention.
15
Study strengths include the use of disease models that have
already been published and applied, consideration of
combinations of interventions, use of a generic measure of
effectiveness, and testing of important assumptions through
sensitivity analyses.
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This study includes a number of modifications in comparison
to the previously published analysis. The higher 2005 price
levelshavegenerallyresultedinhighercosteffectivenessratios,
but these and other modifications have generally not changed
study conclusions. The exception is mass or targeted treatment
with azithromycin in trachoma control, where price reductions
ofazithromycinhaveoffsetgeneralpriceincreasesintheperiod
from 2000 to 2005 and have thus rendered the interventions
more cost effective.
Policy implications
Our results have four major policy implications. Firstly, they
reinforce the fact that cataract surgery and treatment of chronic
otitis media are among the key interventions for combating
vision and hearing impairment.
Secondly, they show that there is a strong economic case to
consider screening for refractive error among schoolchildren.
This supports current efforts within the VISION 2020 initiative
togivegreaterprominencetoscreeningprogrammes.Screening
schoolchildren and adults for hearing disorders is somewhat
less cost effective but is still economically attractive according
to commonly used benchmarks.
Thirdly, inclusion of mass treatment with azithromycin in
programmes to eliminate trachoma needs careful analysis:
although the intervention was cost effective in sub-Saharan
Africa according to commonly used benchmarks, it was not in
SouthEastAsia.However,manyprogrammesaroundtheworld
use donated azithromycin, which makes the intervention
economically more attractive than we have reported here. In
our analysis, trichiasis surgery is more cost effective and thus
provides better value for money.
Fourth, our results show that substantial health gains can be
achieved—up to 32 and 84 million DALYs averted in
sub-Saharan Africa and South East Asia respectively, when
availableeffectiveinterventionsarescaledup.Thiswillrequire
majorresourcemobilisationeffortsatdomesticandinternational
level. Yet, whether such substantial investments are warranted
can only be judged when the findings our present study—that
vision and hearing impairment control interventions are
generally cost effective—are considered in relation to the
economicattractivenessofother,existingornew,interventions
inhealth.Forthisbroaderanalysis,werefertoEvansetal
15and
Chisholm et al,
33 who compare the economic attractiveness of
a wide range of interventions to control, respectively,
communicable and non-communicable diseases.
Contributors: Both authors contributed to the conception, design and
interpretation of data, and drafting of the manuscript. RB performed the
technical analysis. Both authors approved the submitted version of the
manuscript. RB is the guarantor of the manuscript.
Competing interests: All authors have completed the Unified Competing
Interest form at www.icmje.org/coi_disclosure.pdf (available on request
from the corresponding author) and declare: no support from any
organisation for the submitted work; no financial relationships with any
organisations that might have an interest in the submitted work in the
previous three years, no other relationships or activities that could appear
to have influenced the submitted work.
Ethical approval: Ethical approval was not required for this study.
Data sharing: No additional data available
1 World Health Organization. Fact sheet—magnitude and causes of visual impairment .
WHO, 2011. www.who.int/mediacentre/factsheets/fs282/en/.
2 Mathers C, Smith A, Concha M. Global burden of hearing loss in the year 2000 . WHO,
2002. www.who.int/healthinfo/statistics/bod_hearingloss.pdf .
3 Mathers C, Smith A, Concha M. Global burden of adult-onset hearing loss in the year
2002 . WHO, 2005.
4 Smith A, Mathers C. Epidemiology of infection as a cause of hearing loss. In: Newton VE,
Vallely PJ, eds. Infection and hearing impairment . John Wiley, 2006.
5 Mackenzie I, Smith A. Deafness—the neglected and hidden disability. Ann Trop Med
Parasitol 2009;103:565-71.
6 World Health Organization. Fact sheet—deafness and hearing impairment . WHO, 2011.
www.who.int/mediacentre/factsheets/fs300/en/index.html.
7 Vision 2020. Global initiative for the elimination of avoidable blindness. 2011. www.
vision2020.org.
8 World Health Organisation, World Wide Hearing 2009. Seventh workshop on provision
of hearing aids and services for developing countries and WWHearing General Assembly.
Report of workshop and general assembly. 12-13 November 2009. WHO, 2009.
9 Baltussen R, Sylla M, Mariotti SP. Cost-effectiveness analysis of cataract surgery: a global
and regional analysis. Bull World Health Organ 2004;82:338-45.
10 Baltussen RM, Sylla M, Frick KD, Mariotti SP. Cost-effectiveness of trachoma control in
seven world regions. Ophthalmic Epidemiol 2005;12:91-101.
11 Baltussen R, Naus J, Limburg H. Cost-effectiveness of screening and correcting refractive
errors in school children in Africa, Asia, America and Europe. Health Policy 2009;89:201-15.
12 Baltussen R, Smith A. Cost-effectiveness of hearing impairment control in Africa and Asia:
a mathematical modelling approach. Int J Audiol 2009;48:144-58.
13 Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for
national-level priority-setting in the health sector. Cost Eff Resour Alloc 2003;1:8
14 Tan Torres, T, Baltussen RM, Adam T, Hutubessy RC, Acharya A, Evans DB. WHO guide
to cost-effectiveness analysis . WHO, 2003.
15 Evans DB, Lim SS, Adam T, Tan-Torres Edejer T, the WHO-CHOICE MDG Team.
Achieving the Millennium Development Goals for health: a re-examination of intervention
strategies. BMJ 2005;331:1457-61.
16 Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al.
Global data on visual impairment in the year 2002. Bull World Health Organ
2004;82:844-51.
17 Resnikoff S, Pascolini D, Mariotti SP, Pokharel GP. Global magnitude of visual impairment
caused by uncorrected refractive errors in 2004. Bull World Health Organ 2008;86:63-70.
18 World Health Organisation. The global burden of disease: 2004 update . Available at:
www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html.
19 Lauer JA, Murray CJL, Roehrich K, Wirth H. PopMod: a longitudinal four-state population
model with two disease states and comorbidity. Cost Eff Resour Alloc 2003;1:6.
20 Murray CJL, Lopez A. Global burden of disease . World Bank, WHO, Harvard University,
1996.
21 International drug price indicator guide. Introduction. 2011. http://erc.msh.org/mainpage.
cfm?file=1.0.htm&module=Dmp&language=English.
22 Johns B, Baltussen R, Adam T, Hutubessy RCW. Programme costs in the economic
evaluation of health interventions. Cost Eff Resour Alloc 2003;1:1.
23 Johns B, Baltussen R. Accounting for the costs of scaling up health interventions. Health
Econ 2004;13:1117-24.
24 Adam T, Evans DB, Murray CJL. Econometric estimation of country-specific hospital
costs. Cost Eff Resour Alloc 2003;1:3.
25 Unicef. Database on school enrolment. 2008. www.unicef.org/infobycountry/india_
statistics.html.
26 Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of
mortality and disability from diseases, injuries, and risk factors in 1990 and projected to
2020. Harvard University Press, 1996.
27 Limburg H, Kansara HT, d’Souza S. Results of school eye screening of 5.4 million children
in India—a five-year follow-up study. Acta Ophthalmol Scand 1999;77:310-4.
28 Hogeweg M, Sapkota YD, Foster A. Acceptability of aphakic correction. Results from
Karnali eye camps in Nepal. Acta Ophthalmologica 1992;70:407-12.
29 Limburg H, Vaidyanathan K, Dalal HP. Cost-effective screening of schoolchildren for
refractive errors. World Health Forum 1995;16:173-8.
30 Hutubessy RC, Baltussen RM, Evans DB, Barendregt JJ, Murray CJ. Stochastic league
tables: communicating cost-effectiveness results to decision-makers. Health Econ
2001;10:473-7.
31 Salomon J, Carvalho N, Gutierrez-Delgado C, Casey A, Hogan DR, Lee D, et al.
Intervention strategies to reduce burden of non-communicable diseases in Mexico: cost
effectiveness analysis. BMJ 2012;344:e355.
32 Chisholm D, Baltussen, Evans DB, Ginsberg G, Lauer J, Lim S, et al. What are the priorities
for prevention and control of non-communicable diseases and injuries in sub-Saharan
Africa and South East Asia? BMJ 2012;344:e586.
33 Congdon N, Zheng M, Sharma A, Choi K, Song Y, Zhang M, et al. Prevalence and
determinants of spectacle nonwear among rural Chinese secondary schoolchildren: the
Xichang Pediatric Refractive Error Study Report 3. Arch Ophthalmol 2008;126:1717-23.
34 Vincent JE, Netek S, Parry A, Mladenovich D, Thein NN, Amendola PR. Reported wearing
compliance of ready-made spectacles at 6 and 12 months. Optom Vis Sci 2010;87:958-65.
Accepted: 12 October 2011
Cite this as: BMJ 2012;344:e615
This is an open-access article distributed under the terms of the Creative Commons
Attribution Non-commercial License, which permits use, distribution, and reproduction in
any medium, provided the original work is properly cited, the use is non commercial and
is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-
nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e615 doi: 10.1136/bmj.e615 (Published 2 March 2012) Page 5 of 12
RESEARCHWhat is already known on this topic
Several studies have reported on the global and regional cost effectiveness of interventions targeting cataract, trachoma, refractive error
and different causes of hearing impairment.
However, studies have been carried out in isolation, which prevents the cost effectiveness of the different interventions in visual and
hearing impairment control being directly compared.
In addition, these studies have been analysed using year 2000 demographics and price levels
What this study adds
This study directly compares cost and effects of interventions targeting cataract, trachoma, refractive error and different causes of
hearing impairment, using more recent price levels in Sub-Saharan Africa and South East Asia
This allows the identification of most efficient strategies to reduce vision and hearing loss
Tables
Table 1| Prevalence of vision and hearing loss in WHO sub-Saharan African sub-region AfrE, South East Asian sub-region SearD, and the
world (2004 estimates). Values are millions of people (percentages)
World SearD AfrE
6502 1388 402 Total population*
Visual impairment†
Blindness:
17.62 (0.27) 4.25 (0.31) 2.00 (0.50) Cataract
4.53 (0.07) 0.75 (0.05) 0.55 (0.14) Glaucoma
3.21 (0.05) 0.42 (0.03) 0 Age related macular degeneration
1.88 (0.03) 0.25 (0.02) 0.44 (0.11) Corneal opacities
1.77 (0.03) 0.25 (0.02) 0 Diabetic retinopathy
1.44 (0.02) 0.40 (0.03) 0.20 (0.05) Childhood blindness
1.33 (0.02) 0.14 (0.01) 0.27 (0.07) Trachoma
0.29 (0.00) 0 0.07 (0.02) Onchocerciasis
6.84 (0.11) 3.98 (0.29) 0.62 (0.15) Uncorrected refractive error‡
4.79 (0.07) 1.88 (0.14) 0.12 (0.03) Others
43.74 (0.67) 12.32 (0.89) 4.26 (1.06) Total
Low vision:
124.26 (1.91) 28.44 (2.05) 10.57 (2.63) Unspecified
87.94 (1.35) 36.28 (2.61) 1.64 (0.41) Uncorrected refractive error
212.20 (3.26) 64.72 (4.66) 12.21 (3.04) Total
Moderate or greater hearing impairment*
207.28 (3.19) 51.80 (3.73) 5.91 (1.47) Adult onset
46.15 (0.71) 14.38 (1.04) 8.63 (2.15) Child onset
253.42 (3.90) 66.18 (4.77) 14.54 (3.62) Total
*Based on 2004 burden of disease estimates.
18
†Based on Resnikoff et al.
1617 Figures relate to year 2004 and do not match with figures on year 2010 as provided in main text (the latter figures are not yet available
by cause).
‡Estimates in absolute numbers are for ages ≥50 years. Percentages are compared with total population of all ages.
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RESEARCHTable 2| List of interventions considered in cost effectiveness analysis of strategies to combat vision and hearing loss in WHO sub-Saharan
African sub-region AfrE and South East Asian sub-region SearD
Intervention description Intervention code
Trachoma control
Mass treatment tetracycline ointment (50% coverage) TRA-1
Mass treatment azithromycin (50% coverage) TRA-2
Targeted treatment azithromycin (50% coverage) TRA-3
Trichiasis surgery (50% coverage) TRA-4
Mass treatment tetracycline ointment + trichiasis surgery (50% coverage) TRA-5
Mass treatment azithromycin + trichiasis surgery (50% coverage) TRA-6
Targeted treatment azithromycin + trichiasis surgery (50% coverage) TRA-7
Mass treatment tetracycline ointment (80% coverage) TRA-8
Mass treatment azithromycin (80% coverage) TRA-9
Targeted treatment azithromycin (80% coverage) TRA-10
Trichiasis surgery (80% coverage) TRA-11
Mass treatment tetracycline ointment + trichiasis surgery (80% coverage) TRA-12
Mass treatment azithromycin + trichiasis surgery (80% coverage) TRA-13
Targeted treatment azithromycin + trichiasis surgery (80% coverage) TRA-14
Mass treatment tetracycline ointment (95% coverage) TRA-15
Mass treatment azithromycin (95% coverage) TRA-16
Targeted treatment azithromycin (95% coverage) TRA-17
Trichiasis surgery (95% coverage) TRA-18
Mass treatment tetracycline ointment + trichiasis surgery (95% coverage) TRA-19
Mass treatment azithromycin + trichiasis surgery (95% coverage) TRA-20
Targeted treatment azithromycin + trichiasis surgery (95% coverage) TRA-21
Cataract control
Extracapsular cataract extraction with posterior chamber lens implant (50% coverage) CAT-4
Extracapsular cataract extraction with posterior chamber lens implant (80% coverage) CAT-5
Extracapsular cataract extraction with posterior chamber lens implant (95% coverage) CAT-6
Screening for hearing loss†
Annual screening primary school children (50% coverage) HEA-1
Annual screening secondary school children (50% coverage) HEA-2
Annual screening primary and secondary school children (50% coverage) HEA-3
Screening adults every 5 years (50% coverage) HEA-4
Screening adults every 10 years (50% coverage) HEA-5
Passive screening all children and adults (50% coverage) HEA-6
Annual screening primary school children + screening adults every 5 years (50% coverage) HEA-7
Annual screening primary school children + screening adults every 10 years (50% coverage) HEA-8
Annual screening secondary school children + screening adults every 5 years (50% coverage) HEA-9
Annual screening secondary school children + screening adults every 10 years (50% coverage) HEA-10
Annual screening primary and secondary school children + screening adults every 5 years (50% coverage) HEA-11
Annual screening primary and secondary school children + screening adults every 10 years (50% coverage) HEA-12
Annual screening primary school children (80% coverage) HEA-13
Annual screening secondary school children (80% coverage) HEA-14
Annual screening primary and secondary school children (80% coverage) HEA-15
Screening adults every 5 years (80% coverage) HEA-16
Screening adults every 10 years (80% coverage) HEA-17
Passive screening all children and adults (80% coverage) HEA-18
Annual screening primary school children + screening adults every 5 years (80% coverage) HEA-19
Annual screening primary school children + screening adults every 10 years (80% coverage) HEA-20
Annual screening secondary school children + screening adults every 5 years (80% coverage) HEA-21
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RESEARCHTable 2 (continued)
Intervention description Intervention code
Annual screening secondary school children + screening adults every 10 years (80% coverage) HEA-22
Annual screening primary and secondary school children + screening adults every 5 years (80% coverage) HEA-23
Annual screening primary and secondary school children + screening adults every 10 years (80% coverage) HEA-24
Annual screening primary school children (95% coverage) HEA-25
Annual screening secondary school children (95% coverage) HEA-26
Annual screening primary and secondary school children (95% coverage) HEA-27
Screening adults every 5 years (95% coverage) HEA-28
Screening adults every 10 years (95% coverage) HEA-29
Passive screening all children and adults (95% coverage) HEA-30
Annual screening primary school children + screening adults every 5 years (95% coverage) HEA-31
Annual screening primary school children + screening adults every 10 years (95% coverage) HEA-32
Annual screening secondary school children + screening adults every 5 years (95% coverage) HEA-33
Annual screening secondary school children + screening adults every 10 years (95% coverage) HEA-34
Annual screening primary and secondary school children + screening adults every 5 years (95% coverage) HEA-35
Annual screening primary and secondary school children + screening adults every 10 years (95% coverage) HEA-36
Meningitis
Ceftriaxione (50% coverage) MEN-1
Ceftriaxione (80% coverage) MEN-2
Ceftriaxione (95% coverage) MEN-3
Chronic otitis media control
Aural toilet (50% coverage) COM-1
Topical antibiotics (50% coverage) COM-2
Aural toilet (80% coverage) COM-3
Topical antibiotics (80% coverage) COM-4
Aural toilet (95% coverage) COM-5
Topical antibiotics (95% coverage) COM-6
Uncorrected refractive error‡
Annual screening all primary school children (50% coverage) RE-1
Annual screening all secondary school children (50% coverage) RE-2
Annual screening all primary and secondary school children (50% coverage) RE-3
Annual screening children 8 years old (50% coverage) RE-4
Annual screening children 13 years old (50% coverage) RE-5
Annual screening children 8 and 13 years old (50% coverage) RE-6
Annual screening all primary school children (80% coverage) RE-7
Annual screening all secondary school children (80% coverage) RE-8
Annual screening all primary and secondary school children (80% coverage) RE-9
Annual screening children 8 years old (80% coverage) RE-10
Annual screening children 13 years old (80% coverage) RE-11
Annual screening children 8 and 13 years old (80% coverage) RE-12
Annual screening all primary school children (95% coverage) RE-13
Annual screening all secondary school children (95% coverage) RE-14
Annual screening all primary and secondary school children (95% coverage) RE-15
Annual screening children 8 years old (95% coverage) RE-16
Annual screening children 13 years old (95% coverage) RE-17
Annual screening children 8 and 13 years old (95% coverage) RE-18
*Coverage level relates to the geographic coverage of these eligible for intervention.
†Screening for hearing loss is in combination with the provision of hearing aids to those who need it.
‡Screening for uncorrected refractive error is in combination with the provision of spectacles to those who need it.
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RESEARCHTable 3| Model inputs for cost effectiveness analysis of screening strategies for uncorrected refractive error in schoolchildren in WHO
sub-Saharan African sub-region AfrE
Data source Assumption Variable
Target population
Unicef
25 63% Primary school enrolment rate
Unicef
25 27% Secondary school enrolment rate
Health effects
Burden of disease study
26 0.755 Health state valuation of visual impairment
Assumption* 0 Remission rate of uncorrected refractive error (without screening or
treatment)
Calculation† 1.09 Remission rate of uncorrected refractive error (intervention scenarios)
Assumption based on Limburg et al
27 in India;
Hogeweg et al
28 in Nepal‡
70% Compliance with wearing provided glassess
Costs ($Int)
Training§:
Limburg et al
29 in India¶ 165 No of children to screen per teacher (5–10 years old)
50 No of children to screen per teacher (8 years old)
165 No of children to screen per teacher (11–15 years old)
100 No of children to screen per teacher (13 years old)
Assumption* 1 Duration of training (days)
Assumption* 5 Repetition of training (every number of years)
WHO-CHOICE 45 Cost per teacher to train (cost per day)
Screening costs:
Limburg et al
29 in India¶ 1:3.6 Ratio of true positive:false positive cases
Assumption* 4 Useful life of glasses (years)
Assumption* 10 Screening material costs (tape, card etc)
Treatment at health clinic:
Cost of ophthalmic assistant:
Assumption* 15 Time spent per patient (minutes)
WHO-CHOICE 7968 Annual salary
Costs of ophthalmic equipment:
WHO-CHOICE 4 Costs of set
Assumption* 10 Useful life (years)
Assumption* 6400 Average annual patient load
Costs of spectacles:
Assumption* 5 Purchase price
Assumption* 4 Useful life (years)
Costs of outpatient visits:
Limburg et al
29 in India¶ 4.6 No of visits
WHO-CHOICE 500 Costs of visits at secondary hospital level
WHO-CHOICE 3% Discount rate
*Based on personal communication with Dr Mariotti (WHO) and Dr Limburg (independent consultant), both specialists in ophthalmology in low and middle income
settings.
†Formula is −LN(1−(effectiveness×coverage)), with effectiveness equal to compliance and coverage as defined in intervention. The table lists the remission rate
for a coverage of 95%.
‡Estimates based on two studies in the respective regions, and are in line with findings from other studies in China
34 and Thailand.
35
§The number of teachers to train depends on the number of schoolchildren that one teacher can screen and, ultimately, on school size. In screening of children
aged 5–10 years, a trained teacher can serve all classes in the school, on average 165 children. In case only children of aged 8 years are screened, the teacher
can screen only that class, on average 50 children. The same logic applies to screening at secondary school.
¶To our knowledge, this is the only study that provides the required details on costs of screening for refractive error in a low income setting and has therefore been
used as the basis for our estimates.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e615 doi: 10.1136/bmj.e615 (Published 2 March 2012) Page 9 of 12
RESEARCHTable 4| Cost effectiveness of strategies to combat vision and hearing loss in WHO sub-Saharan African sub-region AfrE
Cost effectiveness ratio Annual DALYs
saved per million
population
Annual cost per
capita ($Int) Coverage (%) Disease area and intervention Incremental† Average*
16 16 535 0.01 50 COM-2: Chronic otitis media, topical antibiotics
24 17 638 0.01 80 COM-4: Chronic otitis media, topical antibiotics
63 20 670 0.01 95 COM-6: Chronic otitis media, topical antibiotics
71 71 5843 0.42 80 TRA-11: Trachoma, trichiasis surgery
116 116 5486 0.64 80 CAT-4: Cataract, extracapsular cataract extraction
with posterior chamber lens implant
117 116 6281 0.73 95 CAT-6: Cataract, extracapsular cataract extraction
with posterior chamber lens implant
189 90 6939 0.62 95 TRA-18: Trachoma, trichiasis surgery
190 190 1306 0.25 80 RE-9: Uncorrected refraction error, annual
screening of all schoolchildren‡
217 217 2534 0.55 50 MEN-1: Meningitis, ceftriaxione
521 242 1551 0.38 95 RE-15: Uncorrected refraction error, annual
screening of all schoolchildren‡
735 735 1075 0.79 50 HEA-6: Hearing loss, passive screening of all
children and adults§
766 747 1719 1.28 80 HEA-18: Hearing loss, passive screening of all
children and adults§
806 784 4686 3.67 50 HEA-4: Hearing loss, screening of adults every 5
years§
843 806 7497 6.04 80 HEA-16: Hearing loss, screening of adults every
5 years§
959 263 2702 0.71 80 MEN-2: Meningitis, ceftriaxione
1089 868 9588 8.32 80 HEA-23: Hearing loss, annual screening of
schoolchildren + screening of adults every 5
years§
2654 180 7191 1.29 95 TRA-20: Trachoma, mass treatment with
azithromycin + trichiasis surgery
3066 322 2760 0.89 95 MEN-3: Meningitis, ceftriaxione
3639 1305 11386 14.86 95 HEA-35: Hearing loss, annual screening of school
children + screening of adults every 5 years§
DALYs=disability adjusted life years. $Int=international dollars.
*$Int per DALY averted relative to no intervention.
†$Int per DALY averted, within intervention cluster. This measures the increase in cost divided by the increase in effects when a new intervention is added to an
existing intervention. For example, the incremental cost per DALY averted for screening primary and secondary school children for refractive error is the total
increase in cost divided by the total increase in DALYs averted when screening of primary school children is added to the existing screening of secondary school
children. Incremental ratios are only shown for interventions that are both more effective and less costly than other interventions.
‡Screening for uncorrected refractive error is in combination with the provision of spectacles to those who need it.
§Screening for hearing loss is in combination with the provision of hearing aids to those who need it.
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RESEARCHTable 5| Cost effectiveness of strategies to combat vision and hearing loss in WHO South East Asian sub-region SearD
Cost effectiveness ratio Annual DALYs
saved per million
population
Annual cost per
capita ($Int) Coverage (%) Disease area and intervention Incremental† Average*
14 14 507 0.01 50 COM-2: Chronic otitis media, topical antibiotics
17 14 604 0.01 80 COM-4: Chronic otitis media, topical antibiotics
24 15 634 0.01 95 COM-6: Chronic otitis media, topical antibiotics
56 56 4030 0.23 50 MEN-1: Meningitis, ceftriaxione
97 97 6447 0.63 95 CAT-6: Cataract, extracapsular cataract extraction
with posterior chamber lens implant
100 58 4269 0.25 80 MEN-2: Meningitis, ceftriaxione
112 112 1576 0.18 50 RE-2: Uncorrected refraction error, annual
screening of all secondary school children‡
116 114 2522 0.29 80 RE-8: Uncorrected refraction error, annual
screening of all secondary school children‡
147 122 3405 0.42 80 RE-9: Uncorrected refraction error, annual
screening of all schoolchildren‡
244 62 4352 0.27 95 MEN-3: Meningitis, ceftriaxione
285 285 943 0.27 80 TRA-11: Trachoma, trichiasis surgery
444 173 4044 0.70 95 RE-15: Uncorrected refraction error, annual
screening of all schoolchildren‡
844 844 754 0.64 50 HEA-6: Hearing loss, passive screening of all
children and adults§
849 374 1120 0.42 95 TRA-18: Trachoma, trichiasis surgery
892 862 1207 1.04 80 HEA-18: Hearing loss, passive screening of all
children and adults
1027 987 5055 4.99 50 HEA-11: Hearing loss, annual screening of
schoolchildren + screening of adults every 5 years§
1063 1016 8088 8.22 80 HEA-23: Hearing loss, annual screening of
schoolchildren + screening of adults every 5 years§
4340 1541 9605 14.80 95 HEA-35: Hearing loss, annual screening of school
children + screening of adults every 5 years§
10 860 800 1167 0.93 95 TRA-20: Trachoma, mass treatment with
azithromycin + trichiasis surgery
DALYs=disability adjusted life years. $Int=international dollars.
*$Int per DALY averted relative to no intervention.
†$Int per DALY averted, within intervention cluster. This measures the increase in cost divided by the increase in effects when a new intervention is added to an
existing intervention. For example, the incremental cost per DALY averted for screening primary and secondary school children for refractive error is the total
increase in cost divided by the total increase in DALYs averted when screening of primary school children is added to the existing screening of secondary school
children. Incremental ratios are only shown for interventions that are both more effective and less costly than other interventions.
‡Screening for hearing loss is in combination with the provision of spectacles to those who need it.
§Screening for uncorrected refractive error is in combination with the provision of hearing aids to those who need it.
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RESEARCHFigure
Incremental cost effectiveness ratios and cumulative cost per capita ($Int) of interventions to combat vision and hearing
loss in WHO sub-Saharan African sub-region AfrE. Cost per DALY averted (bars) ranges from very cost effective (such as
treatment of chronic otitis media with topical antibiotics at 50% coverage (COM-2) costing $Int16 per DALY averted) to
least cost effective (annual screening of schoolchildren and screening of adults every five years for hearing loss (HEA-35)
costing $Int3639 per DALY averted). Cumulative cost per capita (dashed line) shows cost if interventions are implemented
in order of decreasing economic attractiveness. In case only COM-2 is implemented, cost per capita is $Int0.01. If all shown
interventions are implemented, costs per capita increase to $Int14.86. See table 4⇓ for descriptions of the intervention
codes
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e615 doi: 10.1136/bmj.e615 (Published 2 March 2012) Page 12 of 12
RESEARCH